智通财经APP获悉，2月21日，恒生指数公司公布最新季检结果，其中华昊中天医药-B(02563)获纳入恒生综合指数成份股，所有变动将于2025年3月7日(星期五)收市后实施并于2025年3月10日(星期一)起生效。据中信证券研报估算，中华昊中天医药-B有可能被纳入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。
近日，华昊中天医药-B发布公告，集团的重要海外管线之一，优替德隆胶囊(UTD2)联合卡培他滨和奥沙利铂一线治疗PD-L1阴性的局部晚期或转移性胃或胃食管交界处腺癌(该联合疗法)的国际多中心II/III期注册临床研究(BG02-2404)已获得美国食品药品管理局(FDA)的批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.